Navigation Links
Velcura Therapeutics, Inc. Can Begin Clinical Trials Following Successful Investigational New Drug Application to U.S. FDA
Date:1/28/2008

ne health. Velcura develops highly differentiated therapies for bone disease; specifically, dual-acting therapies that demonstrate both bone building and anti-bone loss activities in a single molecule. Velcura uses its patented platform technologies to discover and optimize these compounds. Velcura's lead compound, VEL-0230 was identified using these bone assays. More information is at http://www.velcura.com.
Available Topic Expert(s): For information on the listed expert(s), click appropriate link. Michael W. Long, Ph.D. http://profnet.prnewswire.com/Subscriber/ExpertProfile.aspx?ei=49215


'/>"/>
SOURCE Velcura Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Velcura Therapeutics, Inc. Appoints Industry Executive to Lead Regulatory Affairs
2. Former Pfizer Director of Inflammation Molecular Sciences to Spearhead Velcura Therapeutics Inflammatory Disease Initiatives
3. Cell Therapeutics, Inc. (CTI) Prices $1.27 million (euros 856.000) Offering of Common Stock through Societe Generale
4. Cell Therapeutics, Inc. Announces Authorization to Publish Italian Listing Prospectus
5. Cell Therapeutics, Inc. (CTI) Hosts Conference Call to Discuss Update on Zevalin(R) Acquisition, CMS Reimbursement, and PIX301 Timeline
6. Pearl Therapeutics, Inc. Expands Its Senior Management Team With Top Talent in Clinical Development and Regulatory Affairs
7. Cell Therapeutics, Inc. (CTI) to Submit Marketing Authorization Application for XYOTAX(TM) for First-line Non-small Cell Lung Cancer Ahead of Schedule
8. Cell Therapeutics, Inc. Announces Issuance of $23.25 Million in New Convertible Senior Notes in Exchange for $36.08 Million of Existing Convertible Senior Subordinated and Subordinated Notes
9. ARYx Therapeutics, Inc. Announces Pricing of its Initial Public Offering
10. Bioenergy Life Science and Integrative Therapeutics, Inc. Form Exclusive Co-Marketing Alliance
11. Cell Therapeutics, Inc. (CTI) BIO Presentation to Be Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... A new study by researchers from the University ... tiny nanosystems function, unlocking the potential to create ... study, which has been published in the prestigious ... a novel laser technique to examine in rich ... a small cluster containing an acetylene molecule and ...
(Date:7/25/2014)... WABC Radio show out of New York City, ... will be hosting California-based Vet-Stem, Inc.’s Founder and CEO, Robert ... pets. Dr. Harman first visited the show in November ... pets suffering from osteoarthritis and other degenerative diseases, as well ... , Young has invited Dr. Harman back to dial down ...
(Date:7/25/2014)... 25, 2014  Galmed Pharmaceuticals Ltd. (Nasdaq: ... the development and commercialization of a once-daily, oral therapy ... today announced financial results for the period ended June ... , Reported cash and cash equivalents totaling $37.4 ... December 31, 2013.  , Reported a net loss ...
(Date:7/25/2014)... Biotech Ltd. (Nasdaq: SVA ), a leading provider ... announced that it will release its unaudited financial results for ... on Thursday, August 14, 2014 EDT. The Company will host ... August 15, 2014, at 8:00 a.m. EDT (Friday, August 15, ... Company,s financial results and provide an update on recent corporate ...
Breaking Biology Technology:Breakthrough laser experiment reveals liquid-like motion of atoms in an ultra-cold cluster 2Breakthrough laser experiment reveals liquid-like motion of atoms in an ultra-cold cluster 3Robert J. Harman, DVM, Founder and CEO of Vet-Stem, Inc. to Join New York Radio Host Lorry Young in Upcoming Episode of A “Paws” For Your Pet 2Robert J. Harman, DVM, Founder and CEO of Vet-Stem, Inc. to Join New York Radio Host Lorry Young in Upcoming Episode of A “Paws” For Your Pet 3Galmed Pharmaceuticals Reports First Half 2014 Financial Results 2Galmed Pharmaceuticals Reports First Half 2014 Financial Results 3Galmed Pharmaceuticals Reports First Half 2014 Financial Results 4Galmed Pharmaceuticals Reports First Half 2014 Financial Results 5Galmed Pharmaceuticals Reports First Half 2014 Financial Results 6Sinovac to Host Conference Call to Report Second Quarter 2014 Unaudited Financial Results 2
... Researchers Comprise One of the Main User Groups of febit,s ... Simplified and Automated Microarray Technology, MEDFORD, Mass., ... it will introduce the Geniom RT Analyzer(R) to,the U.S. market ... in Boston., RNA-researchers, one of the main user groups ...
... SANTA CLARA, Calif., April 22 /PRNewswire/,-- Agendia BV, ... of molecular,diagnostics, and Agilent Technologies, Inc. (NYSE: ... to collaborate to develop new in-vitro,diagnostic tests. In ... Agendia products will continue to be supplied on ...
... SUPG ), a pharmaceutical company dedicated to the discovery, ... malignancies, invites all interested parties to listen and,view a ... at 9:30 a.m. ET,(6:30 a.m. PT) to approximately 12:00 ... Investors and interested parties may access the webcast ...
Cached Biology Technology:febit to Introduce Geniom RT Analyzer(R) to U.S. Market at RNAi World Congress 2febit to Introduce Geniom RT Analyzer(R) to U.S. Market at RNAi World Congress 3Agendia and Agilent Announce Plans to Jointly Develop New Diagnostic Tests, Extend Supply Agreement 2Agendia and Agilent Announce Plans to Jointly Develop New Diagnostic Tests, Extend Supply Agreement 3
(Date:7/25/2014)... a pleiotropic factor characterized by the existence of ... that confer to the protein deeply different characteristics. ... myelination occurring during development and the different phases ... degeneration, axon regrowth, remyelination and target reinnervation, Researchers ... that the soluble NRG1 upregulation observed in Schwann ...
(Date:7/25/2014)... of a molecular testing panel developed at UPMC ... initial surgery for patients with thyroid nodules and ... Cancer Institute (UPCI), partner with UPMC CancerCenter., The ... and other diagnostic testing agencies, improved the chances ... 30 percent, according to the study published this ...
(Date:7/24/2014)... -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) (the "Company") announced the ... Phase 3 study of Zerenex (ferric citrate), the Company,s ... of hyperphosphatemia in patients with end-stage renal disease (ESRD) ... delivery with FErric CiTrate in EsrD) was published online ... of Nephrology ( JASN ). , ...
Breaking Biology News(10 mins):Test increases odds of correct surgery for thyroid cancer patients 2Test increases odds of correct surgery for thyroid cancer patients 3Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 4
... , AMIA, the association for professionals in biomedical and ... the National Coordinator on Health Information Technology (DHHS/ ONCHIT), ... meaningful use of electronic health records (EHRs) over the ... Policy Committee (HITPC), on the continuation of support for ...
... When patients receive a bone marrow transplant, they are getting ... are needed when a patient is low on red blood ... be caused by cancer or even cancer treatments such as ... transplant might not succeed because the transplanted stem cells don,t ...
... Spanish . Fernando Rendo, biologist at the ... with the intention of completing the genealogical tree ... Country Autonomous Community (CAPVEAE) and Navarre. Concretely, he opted for ... (a kind of variation in the DNA sequence) that can ...
Cached Biology News:AMIA on meaningful use: Invest in people and technology 2How long do stem cells live? 2Basque thesis investigates wide diversity within certain ovine, bovine and equine breeds 2Basque thesis investigates wide diversity within certain ovine, bovine and equine breeds 3
MitoScreen (JC-1) Kit , 100 tests Consult technical datasheet for details....
Large-fragment, single-stranded carrier DNA of the highest quality, perfectly suited for all types of yeast transformation....
... , Customer Peptide Synthesis , 20 Amino Acid length ... 20 mg will return to customer for future usage conjugation ... , Maintenance 102 days/each , ... x5 /each , Test bleed (app. 5 ml) ...
Request Info...
Biology Products: